LEADER 01980nam  2200373   450 
001 9910688469103321
005 20230624084725.0
024 7 $a10.5772/intechopen.91512
035   $a(CKB)5400000000043846
035   $a(NjHacI)995400000000043846
035   $a(EXLCZ)995400000000043846
100   $a20230624d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAdvances in Hepatology /$fedited by Luis Rodrigo [and three others]
210  1$aLondon, England :$cIntechOpen,$d2021.
215   $a1 online resource (258 pages)
311   $a1-83968-625-1 
330   $aThis book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.
606   $aHepatology
606   $aLiver$xDiseases
615  0$aHepatology.
615  0$aLiver$xDiseases.
676   $a616.362
702   $aRodrigo$b Luis
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688469103321
996   $aAdvances in hepatology$92239718
997   $aUNINA